公开(公告)号：US11123348B2

公开(公告)日：2021-09-21

申请号：US16780628

申请日：2020-02-03

Applicant: NOVARTIS AG

Inventor： Agnes Biggart ,  Fang Liang ,  Casey Jacob Nelson Mathison ,  Valentina Molteni ,  Advait Suresh Nagle ,  Frantisek Supek ,  Vince Yeh

IPC: A61K31/519 ,  C07D487/04 ,  C07D519/00 ,  C07F5/02 ,  C07F7/08 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06

Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

公开(公告)号：US10085989B2

公开(公告)日：2018-10-02

申请号：US15600183

申请日：2017-05-19

Applicant: NOVARTIS AG

Inventor： Agnes Biggart ,  Fang Liang ,  Casey Jacob Nelson Mathison ,  Valentina Molteni ,  Advait Suresh Nagle ,  Frantisek Supek ,  Vince Yeh

IPC: A61K31/519 ,  A61K45/06 ,  A61K31/695 ,  A61K31/5377

Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

公开(公告)号：US11066369B2

公开(公告)日：2021-07-20

申请号：US16566083

申请日：2019-09-10

Applicant: Novartis AG

Inventor： Mihai Azimioara ,  Bei Chen ,  Robert Epple ,  Ayako Honda ,  Philip Lam ,  Hasnain Ahmed Malik ,  Casey Jacob Nelson Mathison ,  True Ngoc Nguyen ,  Victor Ivanovich Nikulin ,  Sejal Patel ,  Dean Paul Phillips ,  Rodrigo A. Rodriguez ,  Baogen Wu ,  Xuefeng Zhu

IPC: C07D401/02 ,  C07D213/76 ,  C07D401/14 ,  A61K31/444 ,  C07D401/12 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/5377 ,  A61K45/06 ,  C07D405/14 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D493/08

Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

公开(公告)号：US10596175B2

公开(公告)日：2020-03-24

申请号：US16116418

申请日：2018-08-29

Applicant: NOVARTIS AG

Inventor： Agnes Biggart ,  Fang Liang ,  Casey Jacob Nelson Mathison ,  Valentina Molteni ,  Advait Suresh Nagle ,  Frantisek Supek ,  Vince Yeh

IPC: C07D487/04 ,  A61K31/519 ,  C07D519/00 ,  C07F5/02 ,  C07F7/08 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06

Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

公开(公告)号：US20200002281A1

公开(公告)日：2020-01-02

申请号：US16566083

申请日：2019-09-10

Applicant: Novartis AG

Inventor： Mihai Azimioara ,  Bei Chen ,  Robert Epple ,  Ayako Honda ,  Philip Lam ,  Hasnain Ahmed Malik ,  Casey Jacob Nelson Mathison ,  Truc Ngoc Nguyen ,  Victor Ivanovich Nikulin ,  Sejal Patel ,  Dean Paul Phillips ,  Rodrigo A. Rodriguez ,  Baogen Wu ,  Xuefeng Zhu

IPC: C07D213/76 ,  C07D401/14 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/5377 ,  A61K45/06 ,  C07D405/14 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D493/08

Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

公开(公告)号：US10450273B2

公开(公告)日：2019-10-22

申请号：US15688089

申请日：2017-08-28

Applicant: Novartis AG

Inventor： Mihai Azimioara ,  Bei Chen ,  Robert Epple ,  Ayako Honda ,  Philip Lam ,  Hasnain Ahmed Malik ,  Casey Jacob Nelson Mathison ,  Truc Ngoc Nguyen ,  Victor Ivanovich Nikulin ,  Sejal Patel ,  Dean Paul Phillips ,  Rodrigo A. Rodriguez ,  Baogen Wu ,  Xuefeng Zhu

IPC: C07D213/76 ,  C07D401/14 ,  A61K31/444 ,  C07D401/12 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/5377 ,  A61K45/06 ,  C07D405/14 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D493/08

Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.